Malignant Melanoma

SBIR award to aid development of melanoma peptide vaccine

Published in Drug Week, October 17th, 2003

Generex Biotechnology Corp. (GNBT) announced that the National Cancer Institute has awarded a small business innovative research (SBIR) grant to support development of a novel vaccine for T-helper cell-stimulating peptide vaccines to treat malignant melanoma.

The research will be carried out by Antigen Express, Generex's subsidiary focused on the development of novel immunomedicines.

The grant supports the design, synthesis, and testing of potent Ii-Key/melanoma peptides for possible subsequent clinical studies. The laboratory experiments will be performed in test tubes with lymphocytes from melanoma patients. The most reactive Ii-Key/melanoma...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2003-10-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry